Haleon PLC
Company Profile
Business description
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon’s brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Contact
The Heights
Building 5, First Floor
WeybridgeSurreyKT13 0NY
GBRT: +44 1932959500
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
24,524
Stocks News & Analysis
stocks
Avoid this overvalued ASX lithium producer
stocks
Morningstar's verdict on SpaceX
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,994.70 | 7.20 | -0.08% |
| CAC 40 | 8,340.71 | 59.40 | -0.71% |
| DAX 40 | 24,893.58 | 246.11 | -0.98% |
| Dow JONES (US) | 51,666.84 | 45.87 | -0.09% |
| FTSE 100 | 10,428.85 | 9.00 | -0.09% |
| HKSE | 23,344.67 | 8.39 | 0.04% |
| NASDAQ | 25,587.04 | 579.56 | -2.21% |
| Nikkei 225 | 68,980.21 | 808.17 | -1.16% |
| NZX 50 Index | 13,382.87 | 52.90 | -0.39% |
| S&P 500 | 7,365.46 | 107.33 | -1.44% |
| S&P/ASX 200 | 8,793.00 | 8.40 | -0.10% |
| SSE Composite Index | 4,096.14 | 10.11 | -0.25% |